HBM9036 0.25% Ophthalmic Solution

DRUG2 trials

Sponsors

Harbour BioMed (Guangzhou) Co. Ltd.

Conditions

Dry Eye

Phase 2

A Study Evaluating the Efficacy and Safety on Moderate to Severe Dry Eye

CompletedNCT04092907

Harbour BioMed (Guangzhou) Co. Ltd.Dry Eye

Start: 2019-03-22End: 2019-07-10Updated: 2021-08-11

Phase 3

A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye

CompletedNCT04633213

Harbour BioMed (Guangzhou) Co. Ltd.Dry Eye

Start: 2021-02-25End: 2022-08-07Updated: 2026-04-28

Related Papers

TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China.

2022-02-2222 citations